Karyopharm Therapeutics Cuts 20% of Workforce as Strategic Alternative Search Stalls
核心洞察
Karyopharm Therapeutics has laid off 20% of its workforce as part of ongoing expense management while seeking strategic alternatives including potential mergers or sales.
The oncology biotech company has accumulated a $1.6 billion deficit and is struggling with declining revenue from its approved drug Xpovio, which generated $30 million in Q2 2024.
The company's pipeline centers on eltanexor, an oral XPO1 (搜索) inhibitor for myelodysplastic neoplasms (搜索) that showed a 31% response rate in phase 1/2 trials.
Karyopharm Therapeutics has implemented a second round of layoffs this year, reducing its workforce by 20% as the oncology biotech continues searching for strategic alternatives amid mounting financial pressures. The Massachusetts-based company cited "ongoing careful management of operating expenses" as the reason for the workforce reduction in a July 11 Securities and Exchange Commission filing.
Financial Challenges Mount
The latest cuts follow an earlier reduction-in-force and decrease in external contractors during the first quarter of 2024. While Karyopharm did not specify the exact number of employees affected by the recent layoffs, the company employed 279 full-time workers as of February 14, according to its annual report.
The biotech faces significant financial headwinds, having recorded an accumulated deficit of $1.6 billion at the end of 2023. Revenue from its approved multiple myeloma (搜索) drug Xpovio has been declining, generating approximately $30 million in net product revenue for the most recent quarter—a $5 million decrease compared to the first quarter of 2024.
Strategic Options Under Review
As part of its search for strategic alternatives, Karyopharm has engaged in discussions with investors regarding potential financing transactions. However, these talks have not yielded any deals to date. The company continues to evaluate various options, which could include a merger, sale of the biopharma, in or out of court restructurings, and refinancings of existing debt, according to the SEC filing.
Pipeline Focus on XPO1 Inhibition
Karyopharm's investigational pipeline centers on eltanexor, an oral XPO1 (搜索) inhibitor designed as a monotherapy for myelodysplastic neoplasms (搜索). The drug completed phase 1/2 testing in mid-2023, with interim data showing a 31% overall response rate in the efficacy evaluable population of patients with advanced myelodysplastic neoplasms. The median overall survival reached 8.7 months in this patient group.
The company has stated its current focus involves completing ongoing phase 3 trials for Xpovio in myelofibrosis (搜索) and endometrial cancer (搜索), expanding beyond its approved indication in multiple myeloma (搜索).